Read this response via Medscape:
I previously commented on this thread (March 1st, 2015). Unfortunately, no response from you.
I think that this post finally answer your question “What Does the New York Times Have Against Psychiatry?”
“The World of – – – – – – Psychiatry” – http://wp.me/p4UVo9-1oI
Professor of Pharmacology
University of Valle
Any comment about the CAFE study (Mark Markingson case).
- Psychiatric research misconduct at the University of Minnesota: CAFE study (NCT00034892) — More information about quetiapine | via RxISK.org
- Ethics for drug testing of psychiatric drugs in low and middle-income countries –SOMO
You appear as one of the authors in one paper of the CAFE study.
McEvoy JP, Lieberman JA, Perkins DO, et al. Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatry 2007;164:1050–60. doi:10.1176/ajp.2007.164.7.1050
“At week 52, all-cause treatment discontinuation rates were 68.4%, 70.9%, and 71.4% for olanzapine, quetiapine, and risperidone, respectively.”
Do you have any comment about this information?
3. Why the American Association of Psychiatry have not disclosed their financial reports?
Jorge H. Ramírez